TITLE

Risk of pancreatic adenocarcinoma in chronic pancreatitis

AUTHOR(S)
Malka, D.; Hammel, P.; Maire, F.; Rufat, P.; Madeira, I.; Pessione, F.; Lévy, P.; Ruszniewski, P.
PUB. DATE
December 2002
SOURCE
Gut;Dec2002, Vol. 51 Issue 6, p849
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The risk of pancreatic cancer in patients with chronic pancreatitis (CP) is difficult to assess. Previous studies, mostly case control studies or studies relying on data case registers, reported relative risks varying from 2.3 to 18.5. Methods: We studied a prospective, single centre, medical-surgical cohort of 373 consecutive patients (322 (86%) men, median age 40 years) with proven CP (alcoholic origin 85%) and a follow up of at least two years (median follow up 9.2 years; range 2.0-34.8) in order to exclude pancreatitis revealing pancreatic cancer. We calculated the age and sex standardised incidence ratio (SIR) as the ratio of the number of observed cases of pancreatic cancer in this cohort to the number of expected cases, as provided by the French National Cancer Register. Results: Four cases of pancreatic adenocarcinoma (1.1% of patients) were observed in 3437 patient years (expected number of cases 0.15; SIR 26.7, 95% confidence interval (CI) 7.3-68.3; p=0.00002). In a second analysis in which patients lost to follow up were considered to be followed up until the end point without having developed pancreatic adenocarcinoma (4762 patient years), SIR was 19.0 (CI 5.2-48.8; p=0.00007). Conclusion: Patients with CP have a markedly increased risk of pancreatic cancer compared with the general population.
ACCESSION #
9737565

 

Related Articles

  • Gemcitabine.  // Reactions Weekly;6/5/2010, Issue 1304, p19 

    The article describes the case of a 55-year-old woman who acquired reversible posterior leucoencephalopathy syndrome (RPLS) while undergoing treatment with gemcitabine for metastatic pancreatic adenocarcinoma.

  • Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Rohloff, J.; Zinke, J.; Tannapfel, A.; Witszigmann, H.; Mossner, J.; Wittekind, C.; Caca, K. // British Journal of Cancer;4/22/2002, Vol. 86 Issue 8, p1270 

    Pancreatic ductal adenocarcinoma has a median survival of less than 6 months from diagnosis. This is due to the difficulty in early diagnosis, the aggressive biological behaviour of the turnout and a lack of effective therapies for advanced disease. Mammalian heparanase is a heparan-sulphate...

  • Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Wang, Weixin; Abbruzzese, James L; Evans, Douglas B; Chiao, Paul J // Oncogene;8/12/99, Vol. 18 Issue 32, p4554 

    The Rel/NF-κB transcription factors regulate the expression of many genes. The activity of RelA, a member of the Rel/NF-κB transcription factor family, is constitutively activated in the majority of pancreatic adenocarcinomas and cell lines. We report that the urokinase-type plasminogen...

  • Surgical palliation for ductal adenocarcinoma of the pancreas. Deziel, Daniel J.; Wilhelmi, Bradon // American Surgeon;Jul1996, Vol. 62 Issue 7, p582 

    Presents an evaluation of the short and long term outcomes of operative palliation for unreected ductal adenocarcinoma in a critical review of 319 patients from 1972 to 1990. Overall mortality rate; Biliary enteric anastomosis; Choledochejejunostomy, cholecystojejunostomy and...

  • Pancreatic Cancer: Diagnosis and Management. Freelove, Robert; Walling, Anne D. // American Family Physician;2/1/2006, Vol. 73 Issue 3, p485 

    Although only 32,000 new cases of adenocarcinoma of the pancreas occur in the United States each year, it is the fourth leading cause of cancer deaths in this country. The overall five-year survival rate is 4 percent, and localized, resectable disease has only a 17 percent survival rate. Risk...

  • Serous Microcystic Adenocarcinoma of Pancreas Infiltrating Into Spleen: A Case Report. KADHIRVEL, VALARMATHI; RAMU, SATHYALAKSHMI; MISHRA, NIDHI; ADAIKALAM, MARY LILLY SUSAI; VENKATESAN, RAMYA // Journal of Clinical & Diagnostic Research;Sep2015, Vol. 9 Issue 9, p1 

    Cystic tumours of pancreas account for 5-10% of all pancreatic neoplasms and serous tumours represent 1% among those tumours. Most of the serous tumours are benign and very rarely they infiltrate adjacent organs like liver and spleen. Herewith we present a rare case report of serous...

  • An older woman with diabetes, emesis, and weight loss. Tan, Winston W.; Saunders, Carol S. // Patient Care;4/30/1999, Vol. 33 Issue 8, p163 

    Describes the case study of an elderly diabetic woman with metastatic pancreatic adenocarcinoma. Past medical history of the patient; Signs and symptoms exhibited by the patient; Ability of pancreatic cancer to cause diabetes; Association between diabetes and chronic pancreatitis.

  • CXCR4 positivity linked to liver recurrence, poor survival after PAR. Calabro, Anthony; Shafer, Emily; Taliercio, Adam; Thiel, Bruce; Volansky, Rob // Hem/Onc Today;11/10/2012, Vol. 13 Issue 21, p58 

    The article reports on the results from a study which indicated ties between CXCR4 positivity and lowered survival time and early liver recurrence in patients who underwent resection for pancreatic adenocarcinoma.

  • Antineoplastics.  // Reactions Weekly;1/30/2016, Vol. 1586 Issue 1, p42 

    An abstract of the article "Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma," by C. Tinchon and others is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics